• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels.

作者信息

Rösner Thies, Derer Stefanie, Kellner Christian, Dechant Michael, Lohse Stefan, Vidarsson Gestur, Peipp Matthias, Valerius Thomas

机构信息

Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany.

出版信息

Br J Haematol. 2013 Apr;161(2):282-6. doi: 10.1111/bjh.12209. Epub 2013 Jan 7.

DOI:10.1111/bjh.12209
PMID:23294176
Abstract
摘要

相似文献

1
An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels.利妥昔单抗的一种IgG3转换变体对低CD20表达水平的肿瘤细胞介导增强的补体依赖性细胞毒性。
Br J Haematol. 2013 Apr;161(2):282-6. doi: 10.1111/bjh.12209. Epub 2013 Jan 7.
2
Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.与利妥昔单抗和阿仑单抗相比，II 型、糖基化工程抗 CD20 单克隆抗体 GA101 在 B 慢性淋巴细胞白血病全血检测中的作用机制。
J Immunol. 2011 Mar 15;186(6):3762-9. doi: 10.4049/jimmunol.1000303. Epub 2011 Feb 4.
3
Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL.通过添加新鲜冷冻血浆增强利妥昔单抗在慢性淋巴细胞白血病中的作用：补体/利妥昔单抗相互作用及难治性慢性淋巴细胞白血病的临床结果
Ann N Y Acad Sci. 2009 Sep;1173:865-73. doi: 10.1111/j.1749-6632.2009.04803.x.
4
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.抗CD20抗体（IDEC-C2B8，利妥昔单抗）在体外增强细胞毒性药物对肿瘤淋巴细胞的疗效：细胞因子、补体和半胱天冬酶的作用
Haematologica. 2002 Jan;87(1):33-43.
5
Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.利妥昔单抗输注可促进慢性淋巴细胞白血病患者快速补体耗竭及急性CD20丢失。
J Immunol. 2004 Mar 1;172(5):3280-8. doi: 10.4049/jimmunol.172.5.3280.
6
Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.慢性淋巴细胞白血病患者中 CD16+CD56dim NK 细胞的分析：支持采用优化的抗 CD20 单克隆抗体进行治疗的策略的证据。
Leukemia. 2011 Jan;25(1):101-9. doi: 10.1038/leu.2010.240. Epub 2010 Oct 26.
7
Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.每周三次的低剂量利妥昔单抗通过“刮除”减少CD20丢失，并促进在慢性淋巴细胞白血病中的靶向增强。
J Immunol. 2006 Nov 15;177(10):7435-43. doi: 10.4049/jimmunol.177.10.7435.
8
Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.一种经筛选以改善与FcγRIIIA/CD16结合的抗CD20单克隆抗体可有效杀伤慢性淋巴细胞白血病细胞。
Br J Haematol. 2008 Mar;140(6):635-43. doi: 10.1111/j.1365-2141.2007.06974.x.
9
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.CD20水平决定B细胞慢性淋巴细胞白血病对利妥昔单抗和补体的体外敏感性：CD55和CD59的进一步调节作用
Blood. 2001 Dec 1;98(12):3383-9. doi: 10.1182/blood.v98.12.3383.
10
Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.利妥昔单抗治疗后出现 CD20 阴性表型改变的 10 例 B 细胞非霍奇金淋巴瘤患者的随访数据。
Am J Surg Pathol. 2013 Apr;37(4):563-70. doi: 10.1097/PAS.0b013e3182759008.

引用本文的文献

1
Impact of structural modifications of IgG antibodies on effector functions.IgG 抗体结构修饰对效应功能的影响。
Front Immunol. 2024 Jan 8;14:1304365. doi: 10.3389/fimmu.2023.1304365. eCollection 2023.
2
Complement is activated by elevated IgG3 hexameric platforms and deposits C4b onto distinct antibody domains.补体通过升高的 IgG3 六聚体平台被激活，并将 C4b 沉积到不同的抗体结构域上。
Nat Commun. 2023 Jul 7;14(1):4027. doi: 10.1038/s41467-023-39788-5.
3
Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma.
探究利妥昔单抗同型在 2D 和 3D 培养的 B 细胞淋巴瘤中的补体依赖性细胞毒性。
BMC Cancer. 2022 Jun 20;22(1):678. doi: 10.1186/s12885-022-09772-1.
4
Coming together at the hinges: Therapeutic prospects of IgG3.铰链处相聚：IgG3 的治疗前景。
MAbs. 2021 Jan-Dec;13(1):1882028. doi: 10.1080/19420862.2021.1882028.
5
How Does Complement Affect Hematological Malignancies: From Basic Mechanisms to Clinical Application.补体如何影响血液系统恶性肿瘤：从基础机制到临床应用。
Front Immunol. 2020 Oct 29;11:593610. doi: 10.3389/fimmu.2020.593610. eCollection 2020.
6
Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies.具有增强Fc效应功能的Fc工程化抗体用于治疗B细胞恶性肿瘤
Cancers (Basel). 2020 Oct 19;12(10):3041. doi: 10.3390/cancers12103041.
7
Expression Profiling and Glycan Engineering of IgG Subclass 1-4 in .IgG亚类1-4在……中的表达谱分析与聚糖工程
Front Bioeng Biotechnol. 2020 Jul 24;8:825. doi: 10.3389/fbioe.2020.00825. eCollection 2020.
8
The Ligands for Human IgG and Their Effector Functions.人IgG的配体及其效应功能。
Antibodies (Basel). 2019 Apr 25;8(2):30. doi: 10.3390/antib8020030.
9
A stable engineered human IgG3 antibody with decreased aggregation during antibody expression and low pH stress.一种稳定的工程化人 IgG3 抗体，在抗体表达和低 pH 应激期间降低聚集。
Protein Sci. 2019 May;28(5):900-909. doi: 10.1002/pro.3598. Epub 2019 Mar 22.
10
Antibody Isotypes for Tumor Immunotherapy.用于肿瘤免疫治疗的抗体亚型
Transfus Med Hemother. 2017 Sep;44(5):320-326. doi: 10.1159/000479240. Epub 2017 Sep 7.